FDA Approves HYDROCODONE BITARTRATE AND ACETAMINOPHEN — Rhodes Pharmaceuticals LLC

Rhodes Pharmaceuticals received FDA approval for the ANDA for its generic version of Hydrocodone Bitartrate and Acetaminophen, a move that is expected to intensify market competition for the painkiller. The approval allows the company to undercut the pricing of established branded competitors, a strategy that typically drives significant volume losses for the originator drug. Looking ahead, this development is likely to pressure market share and alter the revenue streams for legacy manufacturers holding the underlying patent.